Three-Plant FDA Warning Spooks Dr Reddy's, Clouds ANDAs
This article was originally published in Scrip
Executive Summary
Dr Reddy's Laboratories was bludgeoned on Indian bourses after the firm said that it had received FDA warning letters at three manufacturing sites, including an oncology plant, in India.
You may also be interested in...
Manufacturing Woes Continue To Plague Dr Reddy’s; Are Generic Gleevec Launch Plans Under Threat?
Dr Reddy’s Laboratories was battered on Indian bourses on March 9 after one of the firm’s formulation sites failed to get a clean chit from the FDA, piling up pressure on important US generic launch timelines.
Manufacturing Woes Continue To Plague Dr Reddy’s; Are Generic Gleevec Launch Plans Under Threat?
Dr Reddy’s Laboratories was battered on Indian bourses on March 9 after one of the firm’s formulation sites failed to get a clean chit from the FDA, piling up pressure on important US generic launch timelines.
How Indian Firms Are Rebooting For Quality Transformation
Against a backdrop of heightened regulatory scrutiny of manufacturing sites and processes, the heads of five top Indian firms told a recent forum in Mumbai how they are “rebooting” quality compliance and culture within their organizations. Tangible and intangible results are beginning to show but there is a long road ahead.